- Topics
- Webcasts & Training
- Events
This timely event will cover the regulatory shift in the U.S. on ESG-centered disclosure; calls for a global, standardized reporting framework; preventing greenwashing in one’s marketing and public relations efforts; third-party risk management; and technology solutions in ESG reporting, monitoring, and benchmarking contexts.
Register
- Resource Library
- Special Reports
- Video
- Membership
Learn from the latest headlines and protect your company today
- Amazon discloses record-shattering $887M GDPR fine
- Compliance ramifications of proposed $26B opioid deal for pharma industry
- Report: Deficient risk culture at Credit Suisse contributed to Archegos collapse
- Ex-KPMG partners barred by SEC over cheating scandal roles
Individual Corporate
Close menu
- Home
-
Topics
- Back to parent navigation item
- Topics
- Accounting & Auditing
- AML
- Anti-Bribery
- Anti-Corruption
- Boards & Shareholders
- Cyber-Security
- Data Privacy
- ESG/Social Responsibility
- Ethics & Culture
- Europe
- Financial Services
- GRC Appointments
- Internal Controls
- Regulatory Enforcement
- Regulatory Policy
- Risk Management
- Sanctions
- Surveys & Benchmarking
- Supply Chain
- Technology
- Third Party Risk
- Whistleblowers
- Compensation
- GDPR
- Internal Investigations
- Opinion
- Training
- Culture
- GRC Announcements
- My Compliance Library
- Ask Amii Mailbag
- Nailed It or Failed It
- Risk and Regulatory Compliance
- Accounting and Audit
- Webcasts & Training
- Events
- Resource Library
- Special Reports
- Video
- Membership
Novartis responds to ongoing corruption investigations
By Jaclyn Jaeger2018-02-12T12:15:00
Novartis has issued a response concerning ongoing corruption investigations by both Greek and U.S. authorities.
WELCOME TO OUR OPEN HOUSE – LOG IN TO CONTINUE READING FOR FREE
If you are already a registered user or a member, SIGN IN now.